Serum Biglycan as a Diagnostic Marker for Non-Alcoholic Steatohepatitis and Liver Fibrosis


Cengiz M., Yilmaz G. , ÖZENİRLER MAYER S.

CLINICAL LABORATORY, vol.67, no.3, pp.804-820, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 67 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.7754/clin.lab.2020.200709
  • Title of Journal : CLINICAL LABORATORY
  • Page Numbers: pp.804-820

Abstract

Background: Non-alcoholic steatohepatitis (NASH) has risen in prevalence substantially through the years. Although course and progression of the disease are variable, fibrosis is the most important factor. We intended to explore utility of serum biglycan (BGN) in NASH and its capacity in anticipating liver fibrosis.